C4 Therapeutics Inc (NASDAQ: CCCC) kicked off on Monday, up 8.16% from the previous trading day, before settling in for the closing price of $2.45. Over the past 52 weeks, CCCC has traded in a range of $1.09-$6.52.
Healthcare Sector giant saw their annual sales slid by -8.92% over the last five years. While this was happening, its average annual earnings per share was recorded -0.82%. With a float of $78.43 million, this company’s outstanding shares have now reached $93.07 million.
C4 Therapeutics Inc (CCCC) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of C4 Therapeutics Inc is 15.73%, while institutional ownership is 60.36%. The most recent insider transaction that took place on Feb 18 ’25, was worth 2,107. In this transaction Chief Business Officer of this company sold 669 shares at a rate of $3.15, taking the stock ownership to the 107,805 shares. Before that another transaction happened on Feb 14 ’25, when Company’s Chief Business Officer sold 490 for $3.15, making the entire transaction worth $1,544. This insider now owns 110,842 shares in total.
C4 Therapeutics Inc (CCCC) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.35 earnings per share (EPS), lower than consensus estimate (set at -0.33) by -0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -0.82% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.42% during the next five years compared to -8.92% drop over the previous five years of trading.
C4 Therapeutics Inc (NASDAQ: CCCC) Trading Performance Indicators
Take a look at C4 Therapeutics Inc’s (CCCC) current performance indicators. Last quarter, stock had a quick ratio of 5.06. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.20.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.58, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.60 in one year’s time.
Technical Analysis of C4 Therapeutics Inc (CCCC)
Analysing the last 5-days average volume posted by the [C4 Therapeutics Inc, CCCC], we can find that recorded value of 2.09 million was better than the volume posted last year of 1.6 million. As of the previous 9 days, the stock’s Stochastic %D was 60.47%.
During the past 100 days, C4 Therapeutics Inc’s (CCCC) raw stochastic average was set at 56.33%, which indicates a significant decrease from 79.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.25 in the past 14 days, which was higher than the 0.22 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.55, while its 200-day Moving Average is $2.24. Now, the first resistance to watch is $2.79. This is followed by the second major resistance level at $2.93. The third major resistance level sits at $3.07. If the price goes on to break the first support level at $2.51, it is likely to go to the next support level at $2.37. Now, if the price goes above the second support level, the third support stands at $2.23.
C4 Therapeutics Inc (NASDAQ: CCCC) Key Stats
The company with the Market Capitalisation of 246.62 million has total of 71,171K Shares Outstanding. Its annual sales at the moment are 35,580 K in contrast with the sum of -105,320 K annual income. Company’s last quarter sales were recorded 6,460 K and last quarter income was -26,020 K.
